Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.63 |
| ▸ | TLR2 | O60603 | 1/20 | 0.59 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872861 | 1.00 | SIGMAR1 (0.63) | SIGMAR1TLR2TLR1ALDH1A1HDAC4 | |
| Hydrochloric Acid SCHEMBL5089349 | 0.99 | SIGMAR1 (0.62) | SIGMAR1TLR2TLR1ALDH1A1HDAC4 | |
| Hydrochloric Acid SCHEMBL5089351 | 0.99 | SIGMAR1 (0.62) | SIGMAR1TLR2TLR1ALDH1A1HDAC4 | |
| SCHEMBL5180920 | 0.87 | SIGMAR1 (0.80) | SIGMAR1TLR2TLR1ALDH1A1DRD2 | |
| SCHEMBL5180929 | 0.87 | SIGMAR1 (0.80) | SIGMAR1TLR2TLR1ALDH1A1DRD2 | |
| SCHEMBL17748295 | 0.86 | SIGMAR1 (0.67) | SIGMAR1TLR2TLR1 | |
| SCHEMBL870999 | 0.84 | SIGMAR1 (0.66) | SIGMAR1TLR2TLR1 | |
| SCHEMBL17117412 | 0.84 | ALDH1A1 (0.64) | SIGMAR1TLR2TLR1ALDH1A1HDAC4 | |
| SCHEMBL10123276 | 0.84 | SIGMAR1 (0.66) | SIGMAR1TLR2TLR1 | |
| SCHEMBL7950428 | 0.84 | SIGMAR1 (0.69) | SIGMAR1TLR2TLR1ALDH1A1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | claimed |
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | disclosed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885TLR2 217/4885TLR1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.